Endoscopic Ultrasound Market: as Olympus's exclusive distribution alliance with Canon Medical finally reaches its planned US commercial launch, a diagnostic ultrasound company that has never sold a GI endoscope is about to become directly responsible for image quality inside one of gastroenterology's highest-value procedures, so the competitive boundary between ultrasound imaging companies and endoscope manufacturers is dissolving in EUS specifically, and the winners will be whichever combination of imaging and endoscope engineering can prove itself fastest in US pancreatic and mediastinal staging cases.

The global endoscopic ultrasound market size was USD 1.48 Billion in 2025 and is expected to register a revenue CAGR of 6.8% during the forecast period. Market revenue growth is driven by factors such as the Olympus-Canon Medical EUS business alliance expanding premium diagnostic ultrasound access, pancreatic cancer diagnosis and staging demand, and EUS fine needle biopsy technology improving tissue acquisition quality. The first driving factor is the Olympus-Canon Medical Systems EUS business alliance, which combines Canon's diagnostic ultrasound imaging expertise with Olympus' established GI endoscope platform and global distribution network. EUS systems and echoendoscopes account for a substantial share of total 2025 market revenue, reflecting the centrality of the core imaging platform to overall EUS market value. The second driving factor is pancreatic cancer diagnosis and staging demand, as EUS remains the preferred modality for characterising pancreatic lesions that other imaging methods cannot adequately resolve. The third driving factor is EUS fine needle biopsy technology improvement, which continues to increase the diagnostic yield of tissue samples obtained during EUS-guided procedures. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way the Olympus-Canon alliance converts one premium diagnostic ultrasound platform into a widening set of regional commercial launches over time, which lets a single underlying imaging technology reach successive geographic markets through Olympus' already-established GI endoscopy distribution and clinical relationships rather than requiring Canon to build separate market access from scratch. Because Olympus already holds deep clinical relationships and distribution infrastructure across gastroenterology departments worldwide, routing Canon's Aplio i800 diagnostic ultrasound technology through that existing channel lets the combined platform reach each new regional market faster than either company's standalone go-to-market approach could achieve independently, so alliance-driven revenue compounds as each successive regional launch builds on the same underlying technology and the same Olympus distribution relationship. As a result, demand and revenue share are concentrating around this alliance as it completes its planned sequence of regional launches, and the forecast reflects the alliance's staged rollout from Japan and Europe toward the United States as a distinct driver of near-term market structure. For instance, the Olympus-Canon Medical Systems alliance, announced in January 2024 with the Aplio i800 EUS diagnostic ultrasound system manufactured by Canon and distributed exclusively by Olympus, is scheduled to reach its US commercial launch in April 2026 following earlier launches in Japan and Europe. These are some of the key factors driving revenue growth of the market.

Because EUS-guided fine needle aspiration and biopsy require substantial specialist training beyond standard endoscopy competency, the pace of EUS adoption is bounded by the supply of adequately trained endosonographers, which grows more slowly than the underlying clinical demand for pancreatic and GI cancer staging.

High capital cost for premium EUS platforms is a second constraint, because a full EUS system, including the echoendoscope, processor, and imaging console, represents a substantial capital investment relative to standard endoscopy equipment, which limits adoption among smaller hospitals and ambulatory centres that lack the procedure volume to justify the expense.

Reimbursement variability for EUS-guided procedures is a third constraint, since coverage and reimbursement rates for EUS fine needle biopsy vary meaningfully by country and payer, which creates inconsistent adoption even where clinical guidelines support EUS as the preferred diagnostic modality for a given indication.

These factors substantially limit endoscopic ultrasound market growth over the forecast period.

The clearest driver of demand is the Olympus-Canon Medical Systems EUS business alliance, which combines Canon's diagnostic ultrasound imaging technology with Olympus' established GI endoscope platform and global distribution and clinical relationships. EUS image quality depends heavily on the underlying ultrasound engine, an area where diagnostic ultrasound specialists like Canon have deeper expertise than endoscope manufacturers historically developing ultrasound capability in-house, so combining Canon's imaging technology with Olympus' endoscope engineering and market access is intended to produce a genuinely differentiated platform rather than an incremental upgrade to either company's existing offering alone. The alliance was announced in January 2024, with Canon developing the Aplio i800 EUS diagnostic ultrasound system and Olympus handling global sales and marketing, launching first in Japan and Europe before a planned US commercial launch in April 2026. The effect on the market is that a diagnostic ultrasound imaging company is becoming directly responsible for image quality inside one of gastroenterology's highest-value procedure categories for the first time. These are some of the key factors driving revenue growth of the market.

The second driver is the sustained scale of pancreatic cancer diagnosis and staging demand, which anchors baseline EUS procedure volume independent of any single technology launch. Pancreatic lesions are frequently difficult to characterise with cross-sectional imaging such as CT or MRI alone, so EUS's ability to obtain high-resolution images and tissue samples directly adjacent to the pancreas through the gastric or duodenal wall has made it the preferred modality for pancreatic mass characterisation and staging in most clinical guidelines. Japan's Pancreatic Cancer Guidelines have specifically recognised EUS as diagnostically equivalent to CT and MRI for certain staging determinations, reinforcing the modality's clinical standing in one of the world's most EUS-experienced healthcare systems. The effect on the market is that EUS procedure volume tracks pancreatic and broader GI cancer incidence trends closely, providing a stable demand floor beneath the market's technology-driven growth layer. These are some of the key factors driving revenue growth of the market.

The Olympus-Canon Aplio i800 alliance launched first in Japan and Europe before its planned April 2026 US debut. A diagnostic ultrasound company is about to become directly responsible for image quality inside gastroenterology's highest-value procedure category.

The third driver is continued improvement in EUS fine needle biopsy needle technology, which increases the diagnostic yield of tissue samples obtained during EUS-guided procedures. A needle design that reliably acquires an adequate tissue core reduces the rate of non-diagnostic or inconclusive biopsy results that would otherwise require a repeat procedure, so incremental needle engineering improvements translate directly into fewer repeat procedures and faster diagnostic pathways for patients with suspected pancreatic or mediastinal malignancy. Cook Medical's EchoTip AcuCore EUS Biopsy Needle, featuring an enhanced cutting tip for superior tissue core acquisition, continues to expand its clinical adoption for pancreatic and mediastinal lesion sampling. The effect on the market is that needle technology improvements are extending the clinical confidence supporting EUS-guided sampling over alternative, more invasive biopsy approaches for hard-to-reach lesions. These are some of the key factors driving revenue growth of the market.

However, the endoscopic ultrasound market faces severe adoption constraints from the specialist training requirement for EUS-guided procedures and high capital cost of premium EUS platforms.

Because EUS-guided fine needle aspiration and biopsy require substantial specialist training beyond standard endoscopy competency, the pace of EUS adoption is bounded by the supply of adequately trained endosonographers, which grows more slowly than the underlying clinical demand for pancreatic and GI cancer staging, particularly outside major academic medical centres.

High capital cost for premium EUS platforms compounds this, because a full EUS system, including the echoendoscope, processor, and imaging console, represents a substantial capital investment relative to standard endoscopy equipment, which limits adoption among smaller hospitals and ambulatory centres that lack the procedure volume to justify the expense.

Reimbursement variability for EUS-guided procedures is the third constraint, since coverage and reimbursement rates for EUS fine needle biopsy vary meaningfully by country and payer, which creates inconsistent adoption even where clinical guidelines support EUS as the preferred diagnostic modality for a given indication.

These factors substantially limit endoscopic ultrasound market growth over the forecast period.

Based on product, the global endoscopic ultrasound market is segmented into EUS systems and echoendoscopes, fine needle aspiration and biopsy needles, EUS processors and consoles, elastography and Doppler add-on modules, and EUS-compatible ancillary devices. EUS systems and echoendoscopes hold the largest revenue share, because the core imaging platform represents the largest single capital purchase in any EUS programme, which suits a market where platform-level investment concentrates the largest revenue category. Fine needle aspiration and biopsy needles are expected to register the fastest revenue growth rate in the global endoscopic ultrasound market over the forecast period, driven by continued needle design improvement increasing diagnostic tissue yield, which is why Cook Medical and comparable needle manufacturers continue to prioritise cutting-tip and core-acquisition engineering.

Pancreatic cancer diagnosis and staging application is expected to account for the largest revenue share in the global endoscopic ultrasound market during the forecast period

Based on application, the global endoscopic ultrasound market is segmented into pancreatic cancer diagnosis and staging, gastrointestinal cancer staging, mediastinal and pulmonary lesion evaluation, and biliary and pancreatic duct disease. Pancreatic cancer diagnosis and staging holds the largest revenue share, because EUS remains the preferred modality for characterising pancreatic lesions that other imaging methods cannot adequately resolve, which ties directly back to the pancreatic cancer demand described in the market's primary demand driver. Mediastinal and pulmonary lesion evaluation is expected to register the fastest revenue growth rate in the global endoscopic ultrasound market over the forecast period, driven by expanding use of EUS-guided sampling as a less invasive alternative to surgical mediastinal staging, which is why pulmonology and thoracic oncology programmes are increasingly adopting EUS-guided workflows.

AI-enhanced EUS image analysis technology is expected to register the fastest revenue growth rate in the global endoscopic ultrasound market during the forecast period

Based on technology, the global endoscopic ultrasound market is segmented into B-mode and harmonic imaging EUS, Doppler and elastography EUS, and AI-enhanced EUS image analysis. B-mode and harmonic imaging EUS holds the largest revenue share, because it remains the foundational imaging technology across nearly all currently deployed EUS platforms, which ties directly back to the core imaging platform investment described in the market's primary demand driver. AI-enhanced EUS image analysis is expected to register the fastest revenue growth rate in the global endoscopic ultrasound market over the forecast period, driven by Medtronic's continued integration of its GI Genius AI capability into EUS-adjacent workflows, which is why manufacturers are prioritising AI-assisted lesion characterisation as a differentiating platform feature.

Based on regional analysis, the endoscopic ultrasound market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of academic GI centres performing complex pancreatic and mediastinal staging procedures sustains premium EUS platform demand, and because Cook Medical, Boston Scientific, and Olympus all maintain their primary commercial presence in the US market. The planned April 2026 US launch of the Olympus-Canon Aplio i800 platform is expected to reinforce North America's position specifically, as the alliance's final planned regional rollout after Japan and Europe. The concentration of academic medical centre EUS training programmes in the country also means new EUS technology is typically adopted in the United States alongside or shortly after initial clinical validation.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The Olympus-Canon alliance launched in Europe alongside Japan as one of its first two regional markets, reflecting the region's established EUS clinical infrastructure. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan and China represent the two largest national markets within the region. Japan served as the first launch market for the Olympus-Canon alliance and maintains the deepest EUS clinical guideline integration globally through its Pancreatic Cancer Guidelines, while China's rapidly expanding GI cancer screening infrastructure leaves considerably more room for growth than in the already EUS-mature Japanese market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early EUS platform adoption among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the precision ultrasound transducer and electronic components that Latin American device distributors depend on, an effect expected to run through 2026 and slow endoscopic ultrasound adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding academic medical centre network and the UAE's regional distribution hubs represent the primary investment centres for endoscopic ultrasound adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist endosonography training infrastructure needed to support EUS adoption at scale.